InstalabLoading...
InstalabLoading...
If your nose is stuffed every morning, your eczema flares without explanation, or your asthma never quite settles, dust mites are one of the most common hidden drivers. Tens of millions of microscopic mites live in mattresses, pillows, and rugs, and your immune system can quietly start treating their proteins as a threat. This blood test tells you whether that is happening inside your body.
Specifically, it measures IgE (immunoglobulin E, an antibody class your body makes against allergens) directed at Dermatophagoides pteronyssinus, the dominant house dust mite species worldwide. A positive result means your immune system has been primed to react to mite proteins. The size of the number, combined with what symptoms you have, helps explain how much your daily exposure is costing you.
The test quantifies how much IgE in your bloodstream specifically binds to D. pteronyssinus mite proteins. Results are reported in kUA/L (kilo-units of allergen-specific antibody per liter), a unit calibrated to a World Health Organization standard. The standard threshold for sensitization is 0.35 kUA/L or higher, though some labs use slightly different cutpoints.
Within the mite, dozens of individual proteins can trigger IgE. Three matter most. Der p 1 and Der p 2 are recognized by 70 to 100 percent of mite-allergic patients in Europe, and Der p 23 by roughly 40 to 70 percent. A research study found that testing only Der p 1 and Der p 2 IgE correctly identified more than 97 percent of European D. pteronyssinus-allergic patients. Component-resolved testing (which measures IgE to individual mite proteins rather than the whole mite extract) is now used to refine diagnosis and predict severity.
Dust mite IgE is one of the strongest signals of perennial allergic rhinitis, the year-round sneezing, congestion, and post-nasal drip that doesn't track with pollen seasons. In a real-world Italian study of 519 mite-allergic patients, Der p 23 was a dominant driver of disease, and 8 percent of patients reacted only to Der p 23 (meaning standard whole-extract testing alone could understate their allergy).
The number itself carries information. In studies of allergic rhinitis patients, moderately elevated serum Der p IgE values (in the 2 to 3 kUA/L range) better predicted who would react to direct nasal challenge with mite extract than the conventional 0.35 kUA/L cutoff. Higher numbers generally mean a higher chance that the mites in your home are actually causing your symptoms, rather than being a coincidental finding.
Dust mite sensitization is a leading cause of allergic asthma, especially in children and young adults. In asthmatic children sensitized to D. pteronyssinus, specific IgE above 44.1 kUA/L was associated with more severe asthma, while values below this threshold appeared more often in milder, intermittent disease.
Broader sensitization, meaning IgE against multiple mite proteins rather than just one, raises the stakes further. Birth-cohort research following children for two decades found that IgE to Der p 1 or Der p 23 by age 5 predicted later asthma. Mite-specific IgE in asthmatic children also tracked with blood eosinophils and exhaled nitric oxide, two markers of active airway inflammation, even when lung function tests still looked normal.
Dust mite allergy is a common but often missed contributor to eczema. In a study comparing adults and children, 95 percent of those with moderate-to-severe atopic dermatitis had D. pteronyssinus-specific IgE, far higher than the 42 percent seen in asthmatics and 17 percent in non-asthmatic controls. If your eczema persists despite topical treatment, this test can identify whether mites in your bedroom are part of the picture.
Specific component patterns matter for severity. Der p 20-specific IgE above 80 kU/L was found in 75 percent of severe atopic dermatitis cases in a German cohort, and IgE to Der p 5 and Der p 21 was enriched among patients with allergic asthma and eczema.
These ranges come from published studies using the ImmunoCAP assay (the most common platform), reported in kUA/L. They are illustrative orientation, not universal targets. Different labs and assays can produce different numbers for the same sample, and a positive IgE on its own does not equal clinical allergy without matching symptoms.
| Tier | Range (kUA/L) | What It Suggests |
|---|---|---|
| Negative | Below 0.35 | No detectable sensitization |
| Low positive | 0.35 to 0.69 | Sensitization present, clinical relevance depends on symptoms |
| Moderate | 0.70 to 17.4 | Sensitization with increasing likelihood of mite-driven symptoms |
| High | 17.5 to 50 | Strong sensitization, frequently associated with active disease |
| Very high | Above 50 | Often seen with severe asthma or atopic dermatitis |
Source: cutoffs from published research (Letran et al. 2021; Kovac et al. 2006; Walsemann et al. 2022; Hong et al. 2018). Compare your results within the same lab over time for the most meaningful trend, since assay variability can shift absolute numbers between platforms.
A finding that surprises many people: 38.3 percent of healthy Japanese blood donors aged 20 to 59 had detectable D. pteronyssinus IgE despite no diagnosed allergy, and 78 percent were sensitized to at least one inhalant allergen. This means a positive result alone does not prove your symptoms are mite-driven. Think of this test as evidence about the immune system's primed state rather than a yes-or-no allergy verdict. The number gains meaning when paired with your actual symptoms, the rooms where they get worse, and other tests like skin prick or, in tougher cases, nasal challenge.
A single dust mite IgE result is a snapshot. Levels shift slowly with age and respond to long-term changes such as immunotherapy or reduced exposure. If you are starting allergen immunotherapy or making major changes to your home environment, retest at 6 to 12 months to see if the trajectory is moving. Patients who responded well to immunotherapy often showed early changes in component-specific IgE and a rising IgG4 (a blocking antibody class) within the first year.
If you are simply confirming a baseline, retesting every 1 to 2 years is reasonable. If you are pregnant, trying to plan a child's environment, or moving into a new home, a fresh measurement helps anchor decisions about bedding, flooring, and humidity control.
A clearly positive result paired with matching symptoms is reason to act. The first step is environmental: encasements for mattresses and pillows, washing bedding weekly in hot water, reducing carpet and upholstery in the bedroom, and keeping indoor humidity below 50 percent. Long-term home avoidance has been shown to reduce sensitization and respiratory disease severity.
If symptoms persist despite environmental control, the next step is an allergist. Sublingual or subcutaneous immunotherapy is the only treatment proven to change the underlying allergic disease rather than just suppress symptoms. A 1607-patient phase III trial of a 300 IR sublingual mite tablet showed significant reduction in rhinitis symptoms and improved quality of life. Companion tests worth considering alongside dust mite IgE include total IgE, an inhalant allergy panel (cat, dog, mold, pollens) to clarify whether you are mono- or polysensitized, and component-resolved testing of Der p 1, Der p 2, and Der p 23 if you are weighing immunotherapy. If your blood test is negative but symptoms strongly suggest mite allergy, ask about local nasal IgE testing or a nasal provocation test.
Evidence-backed interventions that affect your Dust Mite (D. Pteronyssinus) IgE level
Dust Mite (D. Pteronyssinus) IgE is best interpreted alongside these tests.